MRA MELANOMA RESEARCH ALLIANCE

3rd Annual Scientific Retreat

AGENDA

Mayflower Renaissance Hotel
1127 Connecticut Avenue, NW, Washington, DC

Wednesday, February 16th

6:30-8:00 pm **Opening Reception**
Welcome: Debra Black, MRA Co-Founder and Chair of the Board

Thursday, February 17th

8:00-8:15 **Opening Remarks:** Wendy K.D. Selig, MRA President and CEO

8:15-11:25 **Genetic Basis for Melanoma Prevention, Prognostics, and Therapy**
Chair: David E. Fisher

- 8:15-8:40 Identification of novel melanoma risk genes using high-throughput genomics - Kevin Brown, National Cancer Institute
- 8:40-9:05 Transcriptome sequencing to detect gene fusions in melanoma - Nallasivam Palanisamy, University of Michigan
- 9:05-9:30 Insights from sequencing the melanoma transcriptome and exome - Ruth Halaban, Yale University
- 9:30-9:55 Targeting insulin receptor substrates for destruction as a therapeutic modality for treating melanoma - Alexander Levitzki, Hebrew University of Jerusalem
- *9:55-10:10* *Break*
- 10:10-10:35 Pro-invasion metastasis drivers in early stage melanoma are oncogenes - Lynda Chin, Dana-Farber Cancer Institute
- 10:35-11:00 Sulforaphane, a melanoma prevention agent for high-risk MC1R genotypes - Sancy Leachman, University of Utah
- 11:00-11:25 Targeted strategies for melanoma treatment and prevention - David E. Fisher, Massachusetts General Hospital

11:45-1:00 **Lunch**
Keynote address: Michael Milken, MRA Board Member

1:00-1:30 **NIH as a Partner in Advancing Melanoma Research**
Douglas R. Lowy, Deputy Director, National Cancer Institute

1:30-2:30 **MRA Young Investigators**
Chair: Padmanee Sharma, University of Texas MD Anderson Cancer Center

- 1:30-1:50 The role of oncogenic signaling pathways in human melanoma immune evasion - Patrick Ott, New York University
- 1:50-2:10 18F labeled benzamides for preclinical PET imaging of melanoma metastases - Zhen Cheng, Stanford University
- 2:10-2:30 Reactivation of p53 by small molecule inhibitors of the MDM2-p53 interaction as a strategy for the treatment of melanoma - Sanjeev Kumar Shangary, University of Michigan

2:45-5:15 **Adoptive T Cell Transfer: State of the Art**
Chair: Steven Rosenberg, National Cancer Institute

- 2:45-3:10 Manipulating immune regulation in adoptive T-cell therapy for melanoma - Laszlo Radvanyi, University of Texas MD Anderson Cancer Center

	3:10-3:35	Type 17 T cells: a good choice for adoptive T-cell therapy? - Xue-Zhong Yu, Moffitt Cancer Center
	3:35-4:00	Advanced immune monitoring and TCR cloning in clinical trials of T cell receptor (TCR) engineered adoptive cell transfer therapy – Antoni Ribas, University of California Los Angeles
	4:00-4:25	Strategies to enhance the efficacy of adoptive T cell therapy - Cassian Yee, Fred Hutchinson Cancer Center
	4:25-5:15	Tumor infiltrating lymphocytes and genetically modified T cells in the treatment of melanoma and other cancers – Steven Rosenberg, National Cancer Institute
5:15	**Closing Remarks Day 1**: Laura Brockway-Lunardi, MRA Scientific Program Director	

Friday, February 18th

8:00-10:35 **Combinatorial Therapies for More Effective Melanoma Treatment**

Chair: Meenhard Herlyn, The Wistar Institute

	8:00-8:25	A phase I trial of bevacizumab plus ipilimumab in melanoma patients - F. Stephen Hodi, Dana Farber Cancer Institute
	8:25-8:50	Therapeutic inhibition of mutant activated signaling pathways in melanoma: Combinatorial therapy with immune checkpoint blockade - James Allison, Memorial Sloan-Kettering Cancer Center
	8:50-9:15	Immunotherapy of melanoma with toll-enhanced vaccines and blockade of the PD-1 pathway: Toward biomarkers and combinatorial strategies – Drew Pardoll, Johns Hopkins University
	9:15-9:40	Angiogenesis inhibitors and combination chemotherapies - Svetomir N. Markovic, Mayo Clinic Rochester
	9:40-10:05	Identification and validation of combination therapies for melanoma - Levi Garraway, Dana-Farber Cancer Institute
	Short talks:	***Combinatorial therapies to overcome resistance to BRAF(V600E) inhibition***
	10:05-10:20	Melanomas acquire resistance to ^{V600E}B-RAF inhibition by RTK or N-RAS upregulation - Roger Lo, University of California, Los Angeles
	10:20-10:35	Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K - Meenhard Herlyn, The Wistar Institute

10:55-11:55 **Panel Discussion: Regulatory Approval Pathways for New Melanoma Therapies**

Co-chairs: Paul Chapman, Memorial Sloan-Kettering Cancer Center, and F. Stephen Hodi, Dana-Farber Cancer Institute

- Update on RO5185426 (PLX-4032) clinical results - Paul Chapman
- Update on ipilimumab clinical results - F. Stephen Hodi

Panelists:

- Jonathan Cebon, Ludwig Institute for Cancer Research, Melbourne Clinical Sciences Center
- George Demetri, Dana-Farber Cancer Institute
- Richard Pazdur, U.S. Food and Drug Administration
- Adrian Senderowicz, AstraZeneca

11:55-12:00 **Closing Remarks:** Suzanne Topalian, MRA Chief Science Officer